# ALVO catalysts: Alvotech PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/alvo/catalysts

> Alvotech (ALVO) has no upcoming catalysts in this calendar. The latest recorded is the AMJEVITA® (adalimumab) FDA approval, October 20, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ALVO?

Alvotech (ALVO) has no upcoming catalysts in this calendar. The latest recorded is the AMJEVITA® (adalimumab) FDA approval, October 20, 2026. Press release filed with the SEC (EX-99): "REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech's biosimilar to Humira® (adalimumab)." [Calendar and source filings](https://sec-api.dev/companies/alvo/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001171843-26-006704, https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-10-20. Cite: https://sec-api.dev/companies/alvo/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Alvotech |
| Ticker | ALVO (Nasdaq) |
| SEC CIK | 1898416 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/alvo |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2022 | [Biosimilar topline data readout](https://sec-api.dev/pdufa/biosimilar) | ALVO |  | completed, positive | "In July 2022, we initiated the confirmatory clinical study for AVT06 and, in January 2024, we announced positive topline results from the confirmatory study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| December 20, 2022 | [Simlandi (adalimumab-ryvk) complete response letter (CRL)](https://sec-api.dev/pdufa/adalimumab-ryvk) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761299_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| Jan 2023 | [WEZLANA® (ustekinumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed | "In January 2023, we announced that the FDA had accepted for review a BLA for AVT04." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm)) |
| June 28, 2023 | [Simlandi (adalimumab-ryvk) complete response letter (CRL)](https://sec-api.dev/pdufa/adalimumab-ryvk) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761299_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| Oct 2023 | [Alvotech complete response letter (CRL)](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | completed, complete response letter | "October 2023, we announced that we had received a CRL from the FDA which states" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm)) |
| October 11, 2023 | [Selarsdi (ustekinumab-aekn) complete response letter (CRL)](https://sec-api.dev/pdufa/ustekinumab-aekn) | ALVO |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761343_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| Nov 2023 | [Simponi® (simponi) topline data readout](https://sec-api.dev/pdufa/simponi) | ALVO |  | completed, positive | "In November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants (clintrials.gov/study/NCT05632211)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325007451/exh_991.htm)) |
| Jan 2024 | [Alvotech topline data readout](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | completed, positive | "In January 2024, we announced the positive top-line results from a PK study for AVT03 compared to Prolia in healthy adult subjects." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| Jan 2024 | [Eylea® (eylea) topline data readout](https://sec-api.dev/pdufa/eylea) | ALVO | neovascular | completed, positive | "In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with AVT06 (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of the proposed biosimilar to Eylea® in patients with neovascular (wet) AMD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325004011/exh_991.htm)) |
| Jan 2024 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | ALVO | neovascular | completed, positive | "In January 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing the efficacy, safety, and immunogenicity of AVT06 to Eylea® (aflibercept) in patients with neovascular (wet) AMD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325008028/exh_991.htm)) |
| Feb 2024 | [Biosimilar FDA approval](https://sec-api.dev/pdufa/biosimilar) | ALVO |  | completed, approved | "In February 2024, we received U.S. FDA approval for AVT02 as an interchangeable high-concentration citrate-free biosimilar to Humira, AVT02 also qualifies for exclusivity as a high-concentration biosimilar." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| Feb 2024 | [AMJEVITA® (adalimumab) FDA approval](https://sec-api.dev/pdufa/adalimumab) | ALVO |  | completed, approved | "In February 2024, the FDA approved SIMLANDI® (adalimumab-ryvk), the first high-concentration, citrate-free interchangeable biosimilar to Humira® (adalimumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm)) |
| February 23, 2024 | [Simlandi (adalimumab-ryvk) FDA approval](https://sec-api.dev/pdufa/adalimumab-ryvk) | ALVO |  | completed, approved | "BLA761299 ORIG-1: submission_status AP, submission_status_date 20240223, review_priority STANDARD; sponsor_name ALVOTECH USA INC; product SIMLANDI (ADALIMUMAB-RYVK)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761299%22)) |
| February 24, 2024 | [Biosimilar NDA/BLA acceptance](https://sec-api.dev/pdufa/biosimilar) | ALVO |  | completed | "2023, we announced that the FDA had accepted our resubmitted BLA with a February 24, 2024 Biosimilar User Fee Act (BsUFA) goal date." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm)) |
| Apr 2024 | [Simponi® (simponi) topline data readout](https://sec-api.dev/pdufa/simponi) | ALVO | moderate to severe rheumatoid arthritis | completed, positive | "In April 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and the reference product Simponi® in patients with moderate to severe rheumatoid arthritis (clintrials.gov/study/NCT05842213)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325007451/exh_991.htm)) |
| Apr 2024 | [SELARSDI (selarsdi) FDA approval](https://sec-api.dev/pdufa/selarsdi) | ALVO |  | completed, approved | "Alvotech received approval from the FDA for SELARSDI, AVT04 biosimilar to Stelara, in April 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvotechq22025-mda.htm)) |
| Apr 2024 | [Aria® (golimumab) topline data readout](https://sec-api.dev/pdufa/golimumab) | ALVO | moderate to severe rheumatoid arthritis | completed, positive | "In April 2024 Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and Simponi® (golimumab) in patients with moderate to severe rheumatoid arthritis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325006012/exh_993.htm)) |
| Apr 2024 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed, approved | "In April 2024, the FDA approved SELARSDITM (ustekinumab-aekn) as a biosimilar to Stelara® (ustekinumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm)) |
| Apr 2024 | [Alvotech FDA approval](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | completed, approved | "In April 2024 , the FDA approved AVT 04 in a single - dose prefilled syringe for subcutaneous administration for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and in paediatric patients aged six years and older ." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm)) |
| Apr 2024 | [Biosimilar topline data readout](https://sec-api.dev/pdufa/biosimilar) | ALVO |  | completed, positive | "•In April 2024, the Company announced positive topline results from a confirmatory clinical study for AVT05, a proposed biosimilar for Simponi and Simponi Aria." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| April 16, 2024 | [Selarsdi (ustekinumab-aekn) FDA approval](https://sec-api.dev/pdufa/ustekinumab-aekn) | ALVO |  | completed, approved | "BLA761343 ORIG-1: submission_status AP, submission_status_date 20240416, review_priority STANDARD; sponsor_name ALVOTECH USA INC; product SELARSDI (USTEKINUMAB-AEKN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761343%22)) |
| Jul 2024 | [Biosimilar topline data readout](https://sec-api.dev/pdufa/biosimilar) | ALVO |  | completed, positive | "In July 2024, the Company announced positive topline results from a confirmatory patient study for AVT03." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| Oct 2024 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed, approved | "In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325001021/exh_991.htm)) |
| November 13, 2024 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed, approved | "Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has approved a new presentation of SELARSDI (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), in a 130 mg/26 mL single-dose vial for intravenous infusion." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184324006347/exh_991.htm)) |
| Jan 2025 | [Biosimilar NDA/BLA acceptance](https://sec-api.dev/pdufa/biosimilar) | ALVO | with inflammatory conditions | completed | "In January 2025, the FDA accepted our BLA for AVT05 as a proposed biosimilar to Simponi / Simponi Aria (golimumab) for the treatment of patients with inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm)) |
| January 27, 2025 | [Aria® (golimumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/golimumab) | ALVO | with inflammatory conditions | completed | "REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech's proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm)) |
| February 18, 2025 | [PAVBLU® (aflibercept) NDA/BLA acceptance](https://sec-api.dev/pdufa/aflibercept) | ALVO | eye disorders | completed | "On 18 February 2025 , the Company announced that the FDA has accepted for review a BLA for AVT 06 , Alvotech's proposed biosimilar to Eylea (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness ." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm)) |
| February 18, 2025 | [Biosimilar NDA/BLA acceptance](https://sec-api.dev/pdufa/biosimilar) | ALVO | eye disorders | completed | "On 18 February 2025, the Company announced that the FDA has accepted for review a BLA for AVT06, Alvotech's proposed biosimilar to Eylea (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| February 18, 2025 | [Alvotech NDA/BLA acceptance](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | completed | "On 18 February 2025, the Company announced that the FDA has accepted for review a BLA for AVT06." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvo-20250630.htm)) |
| Mar 2025 | [Alvotech NDA/BLA acceptance](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | completed | "In March 2025 , the Company announced the FDA acceptance of its BLA for AVT 03 ." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm)) |
| March 18, 2025 | [Biosimilar NDA/BLA acceptance](https://sec-api.dev/pdufa/biosimilar) | ALVO | osteoporosis in women | completed | "On 18 March 2025, the Company announced the FDA acceptance of BLA for AVT03, a proposed biosimilar to Prolia and Xgeva (denosumab)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| March 18, 2025 | [WEZLANA® (ustekinumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed | "On 18 March 2025, the Company announced the FDA acceptance of BLA for AVT03." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvo-20250630.htm)) |
| March 18, 2025 | [Prolia® (denosumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/denosumab) | ALVO | osteoporosis in women | completed | "On 18 March 2025 , the Company announced the FDA acceptance of BLA for AVT 03 , a proposed biosimilar to Prolia and Xgeva (denosumab) ." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm)) |
| May 5, 2025 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed, approved | "The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325002743/exh_991.htm)) |
| June 25, 2025 | [Alvotech topline data readout](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | completed, positive | "On 25 June 2025, the Company announced the positive topline results from a confirmatory efficacy study comparing AVT23 with the reference biologic." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvo-20250630.htm)) |
| October 31, 2025 | [Avto5 complete response letter (CRL)](https://sec-api.dev/pdufa/avto5) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761462_20251031.pdf%22)) |
| November 2, 2025 | [Aria® (golimumab) complete response letter (CRL)](https://sec-api.dev/pdufa/golimumab) | ALVO |  | completed, complete response letter | "REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325006876/exh_991.htm)) |
| November 24, 2025 | [Avt06 complete response letter (CRL)](https://sec-api.dev/pdufa/avt06) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761435_20251124.pdf%22)) |
| November 26, 2025 | [Avto5 complete response letter (CRL)](https://sec-api.dev/pdufa/avto5) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761461_20251126.pdf%22)) |
| February 5, 2026 | [Biosimilar topline data readout](https://sec-api.dev/pdufa/biosimilar) | ALVO |  | completed, positive | "On 5 February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm)) |
| February 5, 2026 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | ALVO |  | completed, positive | "On 5 February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_993.htm)) |
| March 31, 2026 | [Entyvio® (vedolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/vedolizumab) | ALVO |  | completed | "Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_991.htm)) |
| August 31, 2026 | [Entyvio® (vedolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/vedolizumab) | ALVO |  | completed | "REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326005793/exh_991.htm)) |
| late 2026 | [Alvotech topline data readout](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | scheduled | "Alvotech anticipates receiving U.S. approval by late 2026 for four Biologics License Applications from the U.S. Food and Drug Administration, with minimal impact on the topline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326001773/exh_991.htm)) |
| October 5, 2026 | [AMJEVITA® (adalimumab) FDA approval](https://sec-api.dev/pdufa/adalimumab) | ALVO |  | completed, approved | "REYKJAVIK, Iceland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company's Reykjavik facility." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006383/exh_991.htm)) |
| October 20, 2026 | [AMJEVITA® (adalimumab) FDA approval](https://sec-api.dev/pdufa/adalimumab) | ALVO |  | completed, approved | "REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech's biosimilar to Humira® (adalimumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/exh_991.htm)) |

## Drugs

- [Simlandi (adalimumab-ryvk)](https://sec-api.dev/pdufa/adalimumab-ryvk): 
- [Avt06](https://sec-api.dev/pdufa/avt06): 
- [Avto5](https://sec-api.dev/pdufa/avto5): 
- [Biosimilar](https://sec-api.dev/pdufa/biosimilar): neovascular, with inflammatory conditions, with neovascular, osteoporosis in women, eye disorders
- [Simponi® (simponi)](https://sec-api.dev/pdufa/simponi): moderate to severe rheumatoid arthritis
- [Selarsdi (ustekinumab-aekn)](https://sec-api.dev/pdufa/ustekinumab-aekn): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/alvo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALVO catalysts: Alvotech PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/alvo/catalysts

```bibtex
@misc{secapidev_companies_alvo_catalysts_20261116,
  title        = {ALVO catalysts: Alvotech PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/alvo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_alvo_catalysts_20261116","title":"ALVO catalysts: Alvotech PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/alvo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
